Drugs / MaaT013
MaaT013
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05690048 | Jul 2025 → Mar 2028 expected | hepatocellular carcinoma | Michael Dill | Recruiting | No outcome recorded |
| Phase 2 | NCT04988841 | Jan 2022 → Aug 2024 | melanoma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT03359980 | Aug 2018 → Feb 2020 | — | MaaT Pharma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04769895 | Mar 2022 → Nov 2024 overdue | acute graft versus host disease | MaaT Pharma | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04768907 | — | acute graft versus host disease | MaaT Pharma | Available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MaaT013 | “the first-in-human use of the pooled allogeneic faecal microbiota, MaaT013, for the treatment of steroid-refractory GI-aGvHD” PMID 37654670 ↗ Jul 2023 |
| Known as | Fecal microbiota transfer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05690048 ↗ |
| Known as | INTESTIFIX 001 | “INTESTIFIX 001 is an encapsulated FMT preparation by healthy donors with a high alpha-diversity in their gut microbiome for oral administration, manufactured by the Cologne...” PMID 40930564 ↗ Sep 2025 |
| Action | Restore | “a microbiome restoration biotherapeutic” NCT04988841 ↗ |
| Modality | Other / unclassified | “MaaT013 involved pooling faecal matter from 3 to 8 screened donors then transplanting the pooled batches into patients” PMID 37654670 ↗ Jul 2023 |
| Route | Rectal | “MaaT013 is administered as an enema.” NCT04769895 ↗ |